I.

ANTIALLERGICS
I.A. ANTIHISTAMINES
DOSAGE FORM AND
GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS
STRENGTH
Desloratadine Clarinex Tablets 5mg Long-acting histamine antagonist Relief of nasal and non-nasal symptoms of
with selective H1-receptor seasonal and perennial allergic rhinitis; in
histamine antagonist activity chronic idiopathic urticaria for relief of
symptoms of pruritus and reduction in
number and size of hives.

Cetirizine Zyrtec Tablets 5mg/10mg Competitively antagonizes Symptomatic relief of symptoms (nasal and
histamine at the H1 receptor site nonnasal) associated with seasonal and
perennial allergic rhinitis; treatment of
uncomplicated skin manifestations of
chronic idiopathic urticaria.

Diphenhydramine HCl Benadryl Injection50 mg/mL Competitively antagonizes Symptomatic relief of perennial and
histamine at H1 receptor sites. seasonal allergic rhinitis, vasomotor rhinitis
and allergic conjunctivitis; temporary relief
of runny nose and sneezing caused by
common cold;

Benadryl Allergy Capsules, soft-gels 25 mg; relief of allergic and nonallergic pruritic
Tablets 25 mg;Tablets symptoms; treatment of urticaria and
chewable 12.5 mg; Liquid angioedema; amelioration of allergic
12.5 mg/5 mL reactions to blood or plasma; adjunct to
epinephrine and other standard measures in
anaphylaxis;

AllerMax Allergy and

Cough Formula
relief of uncomplicated allergic conditions of
immediate type when oral therapy is
Liquid 6.25 mg/5 mL
impossible or contraindicated (parenteral
form)

Banophen Capsules 25 mg
 DOSAGE FORM AND
GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS
STRENGTH
Loratadine Claritin Tablets: 10 mg, Tablets, Competitively antagonizes Symptomatic relief (nasal and nonnasal) of
rapidly disintegrating: 10 histamine at the H1-receptor site. symptoms associated with seasonal allergic
mg, Syrup: 1 mg/mL rhinitis; treatment of chronic idiopathic
urticaria.

Hydroxyzine HCl Atarax Tablets 10 mg, 25 mg, 50 May be caused by suppression of Symptomatic relief of anxiety and tension
mg, 100 mg; Syrup 10 mg/5 activity in subcortical areas of associated with psychoneurosis; adjunct
mL CNS. therapy in organic disease states with
anxiety; management of pruritus caused by
allergic conditions; sedative before and after
general anesthesia (PO only).

Vistaril Capsules 25 mg, 50 mg, IM route only: Relief of anxiety in acutely

100 mg; Suspension, oral 25 disturbed or hysterical patient; treatment of
mg/5 mL, Injection 50 alcoholic delirium tremens or anxiety
mg/mL withdrawal symptoms;
 ROUTE OF ADMINISTRATION

Adults and Children Older Than 12

Yr: PO 5 mg once daily. In patients
with renal or hepatic impairment, start
with 5 mg qod.

ADULTS & CHILDREN ³ 6 YR: PO 5

or 10 mg daily.

Hypersensitivity Reactions, Type

1/Antiparkinsonism/Motion Sickness
Adults: PO 25 to 50 mg q 4 to 6 hr
(max, 300 mg/day). IV/IM 10 to 100 mg
(rate not exceeding 25 mg/min or deep
IM; max, 400 mg/day).

Children (6 to under 12 yr): PO 12.5

to 25 mg q 4 to 6 hr (max, 150 mg).
IV/IM 5 mg/kg/day or 150 mg/m2 /day
(max, 300 mg divided into 4 doses at a
rate not exceeding 25 mg/min or deep
IM).

Nighttime Sleep Aid Adults: PO 50

mg at bedtime. Cough Suppressant
(Syrup) Adults: PO 25 mg q 4 hr (max,
150 mg/24 hr). Children (6 to 12 yr):
PO 12.5 mg q 4 hr (max, 75 mg/24 hr).
Children (2 to 6 yr): PO 6.25 mg q 4 hr
(max, 25 mg/24 hr
 ROUTE OF ADMINISTRATION

ADULTS and CHILDREN ³ 6 yr: PO 10

mg once daily. CHILDREN 2 to 5 yr:
PO 5 mg once daily. Hepatic
Impairment ADULTS and CHILDREN ³
6 yr: PO Start with 10 mg every other
day CHILDREN 2 to 5 yr: PO Start
with 5 mg every other day.

Pruritus Adults: PO/IM 25 mg tid to

qid. Children over 6 yr: PO 50 to 100
mg/day in divided doses. Children less
than 6 yr: PO 50 mg/day in divided
doses.

Anxiety Adults: PO/IM 50 to 100 mg

qid Children over 6 yr: PO 50 to 100
mg/day in divided doses. Children less
than 6 yr: PO 50 mg/day in divided
doses.
 II. CARDIOVASCULAR DRUGS
II.A. CALCIUM CHANNEL BLOCKER
DOSAGE FORM AND
GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS
STRENGTH
Nifedipine Adalat Capsules: 10 mg, 20 mg Long-acting histamine antagonist Relief of nasal and non-nasal
with selective H1-receptor symptoms of seasonal and perennial
histamine antagonist activity allergic rhinitis; in chronic idiopathic
urticaria for relief of symptoms of
pruritus and reduction in number and
size of hives.

Adalat CC Tablets, extended-release: Inhibits movement of calcium ions Treatment of vasospastic

30 mg, 60 mg, 90 mg across cell membrane in systemic (Prinzmetal's or variant) angina,
and coronary vascular smooth chronic stable angina, hypertension
muscle and myocardium. (sustained-release tablets only).
Nifedical XL Tablets, extended-release: Increases CO and decreases
30 mg, 60 mg peripheral vascular resistance.
Minimal effect on sinoatrial and
AV nodal conduction. Reduces
Procardia Capsules: 10 mg, 20 mg myocardial oxygen demand;
relaxes and prevents coronary
artery spasm.
Procardia XL Tablets, extended-release:
30 mg, 60 mg, 90 mg

Amlodipine Norvasc Tablets 2.5 mg, 5mg, Inhibits movement of calcium ions Hypertension; chronic stable angina;
10 mg across cell membrane in systemic vasospastic (Prinzmetal's or variant)
and coronary vascular smooth angina.
muscle.
 ROUTE OF ADMINISTRATION

Adults and Children Older Than 12 Yr: PO 5

mg once daily. In patients with renal or hepatic
impairment, start with 5 mg qod.

Capsules: ADULTS: PO 10 mg tid (usual dose

range, 10 to 20 mg tid); swallow whole. Some
patients (eg, coronary artery spasm) respond
only to higher doses administered more
frequently (eg, 20 to 30 mg tid to qid; max 180
mg/day). In hospitalized patients, under close
observation, dose may be increased in 10 mg
increments throughout 4- to 6-hr periods as
required to control pain and arrhythmias
caused by ischemia. A single dose rarely
exceeds 30 mg. Extended-release tablets:
ADULTS: PO Procardia XL and Nifedical XL:
30 or 60 mg once daily, titrated over 7- to 14-
day period (max, 120 mg/day). Adalat CC
(hypertension): Start with 30 mg/day and titrate
dose over 7- to 14-day period (max, 90
mg/day).

ADULTS: PO 5 to 10 mg qd. ELDERLY:

PO Initially 2.5 mg qd. HEPATIC
IMPAIRMENT PO Initially 2.5 mg qd.
 II. CARDIOVASCULAR DRUGS
II.B. BETA-ADRENERGIC BLOCKER

GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS

Acebutolol HCl Sectral, Apo- Blocks beta-receptors, primarily Management of hypertension and
Acebutolol Monitan, affecting heart (slows rate), vascular premature ventricular contractions.
Novo-Acebutolol, Nu- musculature (decreases BP) and
Acebutolol, Rhotral lungs (reduces function).

Atenolol Tenormin, APO- Blocks beta receptors, primarily Treatment of hypertension (used alone or in
Atenol, Gen-Atenolol, affecting heart (slows rate), vascular combination with other drugs), angina
Med-Atenolol, Novo- system (decreases BP) and, to lesser pectoris resulting from coronary
Atenol, Nu-Atenol, extent, lungs (reduces function). atherosclerosis, acute MI. Unlabeled
Schein Pharm use(s): Migraine prophylaxis, alcohol
Atenolol, Taro Atenolol, withdrawal syndrome, ventricular
Tenolin, Tenormin arrhythmias, supraventricular arrhythmias or
tachycardias, esophageal varices
rebleeding, anxiety.

Betaxolol HCl Betoptic, Betoptic S Blocks beta receptors, primarily Hypertension. Ophthalmic preparation:
affecting cardiovascular system Lowering IOP; ocular hypertension; chronic
(decreases heart rate, cardiac open-angle glaucoma.
contractility and BP) and lungs
(promotes bronchospasm).
Ophthalmic use reduces intraocular
pressure, probably by reducing
aqueous production.
 II. CARDIOVASCULAR DRUGS
II.B. BETA-ADRENERGIC BLOCKER

GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS

Metoprolol Lopressor Blocks beta receptors, primarily
affecting cardiovascular system
(decreases heart rate, decreases
contractility, decreases BP) and lungs
(promotes bronchospasm).
Used alone or in combination with
other antihypertensive agents, for
management of hypertension, long-
term management of angina pectoris,
myocardial infarction (immediate-
release tablets and injection).

Nadolol Corgard, Alti-Nadolol, Blocks beta-receptors, which primarily Management of hypertension and angina
Apo-Nadol, Novo- affect cardiovascular system pectoris
Nadolol (decreases heart rate, contractility and
BP) and lungs (promotes
bronchospasm).

Pindolol Visken, Alti-Pindolol, Nonselectively blocks beta receptors, Management of mild-to-moderate

APO-Pindol, Gen- which primarily affect heart (slows hypertension.
Pindolol, Novo-Pindol, rate), vascular musculature
Nu-Pindol (decreases blood pressure) and lungs
(reduces function).
 II. CARDIOVASCULAR DRUGS
II.B. BETA-ADRENERGIC BLOCKER

GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS

Propranolol HCl Betachron E-R, Blocks beta receptors, primarily Treatment of hypertension; angina pectoris;
Inderal, Inderal LA, affecting the cardiovascular system hypertrophic subaortic stenosis; MI;
Propranolol Intensol, (decreased heartrate, decreased pheochromocytoma; migraine prophylaxis;
APO-Propranolol, cardiac contractility and decreased essential tremor; some ventricular and
Detensol, Detensol, BP) and lungs (promotes supraventricular arrhythmias. Unlabeled
Dom-Propranolol, bronchospasm). use(s): Treatment of alcohol withdrawal
Novo-Pranol, Nu- syndrome; esophageal varices rebleeding;
Propranolol, PMS- anxiety; thyrotoxicosis symptoms.
Propranolol
 ROUTE OF ADMINISTRATION
Hypertension
ADULTS: PO 400 mg qd initially in single or divided
doses; usual response range is 200 to 1200 mg/day.

ELDERLY PATIENTS: May require lower

maintenance doses. Do not exceed 800 mg qd.

Ventricular Arrhythmia ADULTS: PO 400 mg (200

mg bid); may be titrated up to 1200 mg qd.

Hypertension ADULTS: PO 50 to 100 mg/day;

Angina Pectoris May require up to 200 mg/day.; Acute
MIIV 5 mg over 5 min; second IV Follow with dose 10
min later. PO 50 to 100 mg/day.

ADULTS: PO 10 to 20 mg/day. ELDERLY: PO

Reduce initial dose to 5 mg/day. Glaucoma Adults:
Ophthalmic 1 to 2 drops bid in affected eye(s).
Consider concomitant therapy if IOP is not at
satisfactory level.
 ROUTE OF ADMINISTRATION
Hypertension ADULTS: PO 100 mg/day in single or
divided doses initially; maintenance: 100–450 mg/day.
Angina ADULTS: PO 100 mg/day in 2 divided doses
initially; maintenance: 100–400 mg/day. Myocardial
Infarction ADULTS: IV bolus injection 5 mg slowly;
may repeat every 2 min up to total of 15 mg. If
tolerated, give PO 50 mg q 6 hr beginning 15 min after
last IV dose; continue for 48 hr followed by PO 100 mg
bid for 1–3 mo. If patient is intolerant of full IV dose,
give PO 25–50 mg q 6 hr starting 15 min after last IV
dose.

Hypertension ADULTS: PO Initiate with 40 mg/day;

titrate in 40 to 80 mg increments to desired response.
Maintenance: 40 to 320 mg/day. Angina ADULTS: PO
Initiate with 40 mg/day; titrate in 40 to 80 mg
increments at 3 to 7 day intervals to desired response.
Maintenance: 40 to 240 mg/day. Dosage intervals may
need to be altered in patients with decreased renal
function.

ADULTS: PO 5 mg bid. May be increased by 10 mg q

3 to 4 wk until desired response; maximum dose is 60
mg/day.
 ROUTE OF ADMINISTRATION
ADULTS: PO Initial dose: 40 mg bid initially or 80 mg
sustained-release medication/day; titrate to response.
Maintenance: 120 to 240 mg/day in 2 to 3 divided
doses or 120 to 160 mg/day sustained-release
medication. Do not exceed 640 mg/day. CHILDREN:
PO 0.5 mg/kg bid; titrate q 3 to 5 days to maximum
dose of 1 mg/kg bid. Angina ADULTS: PO 80 to 320
mg/day in 2 to 4 divided doses or 160 mg/day of
sustained-release medication. Arrhythmias ADULTS:
PO 10 to 30 mg 3 to 4 times/day before meals and at
bedtime. Hypertrophic Aortic Stenosis ADULTS: PO
20 to 40 mg 3 to 4 times/day before meals and at
bedtime or 80 to 160 mg sustained-release medication
1 time/day.
 II. CARDIOVASCULAR DRUGS
II.C. ANTI-ANGINAL DRUGS

GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS

Nitroglycerin Deponit, Minitran, Nitrek, Relaxation of smooth muscle of Treatment of acute angina (SL,
Nitro-Bid, Nitro-Bid IV, Nitro- venous and arterial vasculature. translingual, IV, transmucosal);
Dur, Nitro-Time, Nitrodisc, prophylaxis of angina (SL, transmucosal,
Nitrogard, Nitroglyn, Nitrol, translingual, sustained release,
Nitrolingual, transdermal, topical); control of blood
pressure in perioperative or intraoperative
hypertension (IV); CHF associated with MI
(IV)

Isosorbide Mononitrate ISMO, Imdur, Monoket, Relaxation of smooth muscle of Prevention of angina pectoris.
Isotrate ER venous and arterial vasculature.

Isosorbide Dinitrate Dilatrate-SR, Isordil, Isordil Relaxation of smooth muscle of Treatment and prevention of angina
Tembids, Isodril Titradose, venous and arterial vasculature. pectoris.
Sorbitrate, APO-ISDN,
Cedocard-SR
 II. CARDIOVASCULAR DRUGS
II.C. ANTI-ANGINAL DRUGS

GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS

 ROUTE OF ADMINISTRATION
Perioperative Hypertension ADULTS IV 5 mcg/min
using nonperipheral vein catheter (PVCP) IV
administration set initially; titrate to response. Angina
ADULTS SL 0.15 to 0.6 mg dissolved under tongue or
in buccal pouch at first sign of acute angina attack;
repeat q 5 min (do not exceed 3 tablets in 15 min).
Translingual 1 to 2 sprays onto or under tongue at
first onset of attack. Transmucosal 1 mg every 3 to 5
hr during waking hours; tablet placed between lip or
cheek and gum. PO 2.5 or 2.6 mg (sustained-release
form) tid to qid initially; titrate to response.
Transdermal 0.2 to 0.4 mg/hr patch initially applied
once daily; titrate dose to response. Topical 1 to 2
inches q 8 hr up to 4 to 5 inches spread over 3 x 4 inch
area and cover with plastic wrap to prevent staining of
clothes or application q 4 hr prn. Allow a nitrate-free
period of 10 to 12 hr/day.

Hypersensitivity to nitrates; severe anemia; closed-

angle glaucoma; orthostatic hypotension; head trauma
or cerebral hemorrhage.

Angina Pectoris ADULTS: SL (sublingual tablets) 2.5

to 5 mg; PO (chewable tablets) 5 mg; PO (oral tablets)
5 to 40 mg q 6 hr; PO (sustained release tablets) 40 to
80 mg q 8 to 12 hr. Acute Prophylaxis ADULTS: PO
(sublingual or chewable tablets) 5 to 10 mg q 2 to 3 hr.
ROUTE OF ADMINISTRATION

GENERIC NAME BRAND NAME
Dobutamine Dobutrex
Dopamine HCl Intropin, Revimine
Epinephrine Adrenalin Chloride Solution:
0.1%, 1 mg/mL as HCl; Ana-
Kit Asthma Nefrin Solution for
inhalation: 2.25%; Nephron:
Solution for inhalation: 2.25%
racepinephrine HCl (1.125%
epinephrine
base)racepinephrine HCl
(1.125% epinephrine base);
Epifri: Solution: 0.5%, 1%,
2%
II. CARDIOVASCULAR DRUGS
II.D. VASOPRESSOR
MODE OF ACTION
Stimulates beta1-receptors in
heart, causing more complete
and forceful contractions
(inotropy) without significantly
increasing heart rate or BP.
Stimulates beta1 receptors in
heart, causing more complete
and forceful contractions
(inotropy). Also acts on alpha
receptors (dose dependent) and
has dopaminergic effects.
Stimulates both alpha-and beta-
receptors (alpha-receptors at
high doses; beta1 - and beta2
-receptors at moderate doses)
within sympathetic nervous
system. Relaxes smooth muscle
of bronchi and iris and is
antagonist of histamine.
INDICATIONS
Treatment of cardiac decompensation
caused by organic heart disease or
cardiac surgical procedures. Unlabeled
use(s): Congenital heart disease in
children undergoing diagnostic cardiac
catheterization.
Correction of hemodynamic imbalances
present in shock after MI; trauma,
endotoxic septicemia, surgery and renal
failure or imbalances in conditions of
chronic refractory cardiac decompensation
(eg, CHF).
Treatment and prophylaxis of cardiac
arrest and attacks of transitory
atrioventricular heart block; treatment of
Adams-Stokes syndrome; treatment of hay
fever; relief of bronchial asthma; treatment
of syncope caused by heart block or
carotid sinus hypersensitivity; symptomatic
relief of serum sickness, urticaria and
angioedema; relaxation of uterine
musculature; anaphylaxis;
 II. CARDIOVASCULAR DRUGS
II.D. VASOPRESSOR

GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS

 ROUTE OF ADMINISTRATION
ADULTS: IV infusion 2.5 to 10 mcg/kg/min; titrate to
desired response; increase in heart rate > 10% may
develop in rate > 20 mcg/kg/min; rates up to 40
mcg/kg/min are rarely used. Duration of therapy up to
72 hr without decrease in clinical effectiveness may be
used.

ADULTS: IV Initial dose: 2 to 5 mcg/kg/min with

incremental changes of 5 to 10 mcg/kg/min at 10 to 15
min intervals until adequate response is noted. Most
patients are maintained at < 20 mcg/kg/min. If dosage
exceeds 50 mcg/kg/min, assess renal function
frequently.

Cardiac Arrest ADULTS: IV/Endotracheal/Intracardiac

0.5 to 1 mg (5 to 10 mL of 1:10,000 solution) q 5 min
prn. Myocardial injection usually given in left
ventricular chamber by trained personnel at dose of
0.3 to 0.5 mg. Other IV Uses ADULTS: IV 1 mg in 250
mL of D5W (4 mcg/mL) for infusion at 1 to 4 mcg/min
(15 to 60 mL/hr). Intraspinal Use ADULTS: Intraspinal
0.2 to 0.4 mL of 1:1000 solution added to anesthetic
spinal fluid mixture. Epinephrine 1:100,000 to
1:200,000 is usual concentration employed with local
anesthetics.
ROUTE OF ADMINISTRATION
 III. RESPIRATORY DRUGS
III.A. ANTITUSSIVES
DOSAGE FORM AND
GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS
STRENGTH
Dextromethorphan Robitussin Cough Calmers Lozenges: 5 mg; Liquid: 7.5 Suppresses cough by central Management of nonproductive cough.
Hydrobromide Robitussin Pediatric; Scot- mg/5 mL; Lozenges:2.5 mg; action on cough center in medulla.
Tussin DM Cough Chasers; Syrup:10 mg/5 mL; Liquid:
Silphen DM; Vicks Dry 15 mg/5 mL
Hacking Cough

Levodropropizine Symptomatic Relief of Cough

III.B. DECONGESTANTS
Phenylpropanolamine AP Histallin; Altussan; Tablet: 500 mg; Syringe 60 Phenylpropanolamine, a Symptomatic relief of respiratory conditions
HCl/Guaifenesin Decolgen Forte; BioFlu; mL; 120 mL; Caplet: 500 sympathomimetic amine, causes characterized by nasal congestion and dry,
Disudrin mg; Syringe 12.5 mg/5 mL x constriction and shrinkage of nonproductive cough in presence of mucus
60 mL; Drops 6.25 mg/mL x mucous membranes, resulting in in respiratory tract.
10 mL less nasal stuffiness and improved
drainage and ventilation.
Guaifenesin enhances output of
respiratory tract fluid by reducing
adhesiveness and surface tension
of viscous mucus.

Diphenhydramine HCl AllerMax Tablets 50 mg Competitively antagonizes Symptomatic relief of perennial and
histamine at H1 receptor sites. seasonal allergic rhinitis, vasomotor rhinitis
and allergic conjunctivitis; temporary relief
of runny nose and sneezing caused by
common cold; relief of allergic and
 DOSAGE FORM AND
GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS
STRENGTH Competitively antagonizes Symptomatic relief of perennial and
AllerMax Allergy and Liquid 6.25 mg/5 mL histamine at H1 receptor sites. seasonal allergic rhinitis, vasomotor rhinitis
Cough Formula and allergic conjunctivitis; temporary relief
of runny nose and sneezing caused by
Banophen Capsules 25 mg common cold; relief of allergic and
Benadryl Injection 50 mg/mL nonallergic pruritic symptoms; treatment of
Benadryl Allergy Capsules, soft-gels 25 mg urticaria and angioedema; amelioration of
Tablets 25 mg; Tablets, allergic reactions to blood or plasma;
chewable 12.5 mg Liquid
12.5 mg/5 mL

III.C. CORTICOSTEROIDS
Hydrocortisone (Cortisol) Hydrocortisone Buteprate Short-acting glucocorticoid that Treatment of primary or secondary adrenal
Pandel; Hydrocortisone depresses formation, release, and cortex insufficiency, rheumatic disorders,
Butyrate Locoid; activity of endogenous mediators collagen diseases, dermatologic diseases,
Hydrocortisone of inflammation including allergic states, allergic and inflammatory
Cypionate Cortef; prostaglandins, kinins, histamine, ophthalmic processes, respiratory diseases,
Hydrocortisone liposomal enzymes, and hematologic disorders (idiopathic
Phosphate Hydrocortisone complement system. Also modifies thrombocytopenic purpura), neoplastic
Phosphate;Hydrocortison body's immune response. diseases, edematous states (resulting from
e Sodium Succinate A- nephrotic syndrome), GI diseases
Hydrocort, Solu-Cortef (ulcerative colitis and sprue), multiple
sclerosis, tuberculous meningitis, trichinosis
with neurologic or myocardial involvement.
 DOSAGE FORM AND
GENERIC NAME BRAND NAME MODE OF ACTION INDICATIONS
STRENGTH
Beclomethasone Beclovent Aerosol: 42 mcg/actuation Has potent anti-inflammatory effect Oral inhalation: QVAR: Maintenance
Dipropionate on respiratory tract and in nasal prophylactic treatment of asthma; asthma
passages. patients requiring systemic corticosteroid
Beconase Aerosol: 42 mcg/actuation
administration where adding an inhaled
corticosteroid may reduce or eliminate need
for systemic corticosteroids.
Beconase AQ Spray: 0.042%
beclomethasone
dipropionate, monohydrate

Vancenase Aerosol: 42 mcg/actuation

Budesonide Pulmicort Turbuhaler Powder: 200 mcg (each
actuation delivers
approximately 160
mcg)/metered dose
Pulmicort Respules Inhalation suspension: 0.25
mg/2 mL
Inhalation suspension: 0.5
mg/2 mL
Rhinocort Aerosol: approximately 32
mcg micronized
budesonide/actuation. With
propellants.
Exerts potent anti-inflammatory
effect on nasal passages.
Intranasal: Management of seasonal and
perennial allergic rhinitis symptoms in adults
and children (Rhinocort, Rhinocort Aqua);
management of nonallergic perennial rhinitis
in adults (Rhinocort only). Oral inhalation:
For the maintenance treatment of asthma
as prophylactic therapy in adults and
children and for patients requiring oral
corticosteroid therapy for asthma (inhaler).
 ROUTE OF ADMINISTRATION

Gelcaps Adults and children (at least

12 yr): PO 30 mg q 6 to 8 hr (max, 120
mg/day). Lozenges Adults and children
(at least 12 yr) PO 5 to 15 mg q 1 to 4
hr (max, 120 mg/day). Children (6 to
under 12 yr): PO 5 to 10 mg q 1 to 4 hr
(max, 60 mg/day). Liquid and syrup
Adults and children (at least 12 yr): PO
10 to 20 mg q 4 hr or 30 mg q 6 to 8 hr
(max, 120 mg/day). Children (6 to
under 12 yr): PO 15 mg q 6 to 8 hr
(max, 60 mg/day). Children (2 to under
6 yr): PO 7.5 mg q 6 to 8 hr (max, 30
mg/day). Extended-release
suspension Adults and children (at
least 12 yr): PO 60 mg q 12 hr (max,
120 mg/day). Children (6 to under 12
yr): PO 30 mg q 12 hr (max, 60
mg/day). Children (2 to under 6 yr): PO
15 mg q 12 hr (max, 30 mg/day).

ADULTS: PO 25 mg
phenylpropanolamine/100 to 400 mg
guaifenesin q 4 hr (immediate release
tablets) or 75 mg
phenylpropanolamine/100 to 600 mg
guaifenesin q 12 hr (sustained release
tablets). CHILDREN: PO 6.25 to 12.5
mg phenylpropanolamine/50 to 200 mg
guaifenesin q 4 hr.

Nighttime Sleep Aid Adults: PO 50 mg

at bedtime. Cough Suppressant
(Syrup) Adults: PO 25 mg q 4 hr (max,
150 mg/24 hr). Children (6 to 12 yr):
PO 12.5 mg q 4 hr (max, 75 mg/24 hr).
 ROUTE OF ADMINISTRATION
Nighttime Sleep Aid Adults: PO 50 mg
at bedtime. Cough Suppressant
(Syrup) Adults: PO 25 mg q 4 hr (max,
150 mg/24 hr). Children (6 to 12 yr):
PO 12.5 mg q 4 hr (max, 75 mg/24 hr).
Children (2 to 6 yr): PO 6.25 mg q 4 hr
(max, 25 mg/24 hr).

HYDROCORTISONE BUTEPRATE
ADULTS & CHILDREN: Topical Apply
thin film to affected area bid.
HYDROCORTISONE BUTYRATE
ADULTS & CHILDREN: Topical Apply
sparingly to affected areas bid to qid.
HYDROCORTISONE AND
HYDROCORTISONE CYPIONATE
ADULTS & CHILDREN: PO 20 to 240
mg/day. HYDROCORTISONE
SODIUM PHOSPHATE ADULTS &
CHILDREN: IV/IM/SC 15 to 240
mg/day.
 ROUTE OF ADMINISTRATION

Children (6 to 12 yr): PO inhalation 1

to 2 inhalations tid to qid or 4
inhalations bid. Do not exceed 10
inhalations/day. Adults and children (12
yr and older): PO QVAR: If previous
therapy consisted of bronchodilators
alone, start with 40 or 80 mcg bid (max
dose, 320 mcg bid); if previous therapy
consisted of inhaled corticosteroids,
start with 40 to 160 mcg bid (max dose,
320 mcg bid).

Turbuhaler (Rhinocort) Adults and

Children at least 6 yr: Intranasal Initial
dose: 256 mcg/day, given as 2 sprays
in each nostril in the morning and
evening or 4 sprays in each nostril in
the morning. Maintenance: Smallest
amount necessary to control symptoms
(max, 4 spray/nostril daily). Rhinocort
Aqua Adult and Children at least 12 yr: